Moderna 8-K
Leadership change
Chief Legal Officer Klinger to retire March 2027 with $1.63M severance and conditional payouts tied to Arbutus/Genevant and Pfizer/BioNTech litigation.
Filed 2026-11-13 16:01 ET
- 5.02 Officer/director change
- 9.01 Financial Statements and Exhibits
Summary
Chief Legal Officer Shannon Thyme Klinger retirement agreement. She will remain employed through 03/31/2027, transition her duties, and resign from all officer positions by that date or an earlier date designated by the company.
Key Figures
- Through her retirement date, Klinger will continue to receive her current salary and benefits, vest in outstanding equity awards, and be eligible for a 2026 performance bonus based on her target bonus and the board-determined corporate performance factor.
- Severance: $1.63M, paid in substantially equal installments over 12 months after the retirement date, plus COBRA premiums through 09/30/2028, subject to earlier termination if she obtains other health coverage or loses COBRA eligibility.
- Conditional litigation payments: $2.5M if the company prevails in its current and related future proceedings with Arbutus Biopharma and Genevant Sciences; up to $5.5M based on the outcome of current and related future proceedings with Pfizer, BioNTech and related parties.
Get emails when companies you follow file: email digest settings.
The summary is written by an AI model reading the filing.
Model 005 · prompt v192 · 2026-11-13 23:34:06Z